GEN SLC22A7 - MỘT CHỈ THỊ SINH HỌC TIỀM NĂNG TRONG CHẨN ĐOÁN VÀ TIÊN LƯỢNG BỆNH UNG THƯ BIỂU MÔ TẾ BÀO GAN

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Xuân Thế Hoàng, Đình Biên Lại, Minh Nam Nguyễn, Thị Thu Huyền Nguyễn, Văn Gió Nguyễn, Công Mạnh Trần, Quỳnh Hoa Trần

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Khoa học Công nghệ và Thực phẩm (Tên mới: Tạp chí Khoa học Đại học Công Thương), 2020

Mô tả vật lý: tr.103

Bộ sưu tập: Metadata

ID: 313141

Thêm vào giỏ Liên kết toàn văn

Gen SLC22A7 (SLC22A7) thuộc họ SLC22A, mã hóa cho protein OAT2 tham gia chính trong quá trình vận chuyển anion hữu cơ không phụ thuộc ion natri ở tế bào gan và thận. Ung thư biểu mô tế bào gan (HCC) là căn bệnh phức tạp và có tỷ lệ tử vong cao. Tìm kiếm các chỉ thị sinh học có thể chẩn đoán sớm và tiên lượng bệnh ung thư biểu mô tế bào gan là rất cần thiết nhằm hạn chế các gánh nặng của HCC gây ra cho bệnh nhân, gia đình và xã hội. Trong báo cáo này, nhóm tác giả đã sử dụng phương pháp tin sinh học để nghiên cứu sự biểu hiện của SLC22A7 trong tế bào, trên các mô và mối tương quan của chúng với bệnh ung thư biểu mô tế bào gan. Kết quả cho thấy rằng SLC22A7 biểu hiện chủ yếu ở gan, đặc biệt trên màng tế bào gan. Mô ung thư HCC có biểu hiện SLC22A7 thấp hơn mô không ung thư. Bệnh nhân ung thư biểu mô tế bào gan biểu hiện mRNA của SLC22A7 thấp cho thấy sự tiên lượng xấu. Nghiên cứu này chứng tỏ rằng SLC22A7 là một chỉ thị sinh học tiềm năng trong việc chẩn đoán sớm và tiên lượng bệnh ung thư biểu mô tế bào gan.Từ khóa: SLC22A7, chỉ thị sinh học, chẩn đoán, tiên lượng, ung thư, HCC.The SLC22A7 gene belongs to the SLC22A family and encodes for the OAT2 protein involved in the sodium-independent transport and excretion of organic anions in the liver and kidney. Hepatocellular carcinoma (HCC) is a complex disease and has a high mortality rate. Identifying biomarkers that can be used to diagnose early and prognosis of HCC is essential to reduce the burden of HCC on patients, families, and society. In this report, we used bioinformatics tools to study the expression of SLC22A7 in the cell, on the tissues and their correlation with hepatocellular carcinoma. Our results showed that SLC22A7 mainly expresses in the liver, especially on the membrane of liver cells. We also found that level expression of SLC22A7 in liver cancer tissues was lower than that in non-cancer tissues. Low expression of SLC22A7 was related to worse prognosis in patients with HCC. Taken together, we indicated that SLC22A7 is a potential biomarker for early diagnosis and prognosis of hepatocellular carcinoma.Keywords: SLC22A7, biomarker, diagnosis, prognosis, cancer, HCC

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR